SCHEMBL1384151

SCHEMBL1384151

Cc1cccc(NC(=O)Nc2ccc(-c3ccc(F)c4noc(N)c34)cc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.65
FLT3 P36888 17/20 0.65
PDGFRB P09619 5/20 0.65
KIT P10721 14/20 0.64
CSF1R P07333 6/20 0.55
FLT1 P17948 6/20 0.55
LCK P06239 5/20 0.55
FLT4 P35916 5/20 0.55
AURKA O14965 4/20 0.55
ROCK2 O75116 4/20 0.55
RPS6KB1 P23443 4/20 0.55
AURKB Q96GD4 4/20 0.55
BLK P51451 4/20 0.55
RPS6KA5 O75582 3/20 0.55
PRKD3 O94806 3/20 0.55
MAP4K4 O95819 3/20 0.55
RET P07949 3/20 0.55
FGFR1 P11362 3/20 0.55
FER P16591 3/20 0.55
AXL P30530 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4739605 0.90 KDR (0.67) KDRFLT3PDGFRBKITCSF1R
SCHEMBL1382149 0.89 KDR (0.65) KDRFLT3PDGFRBKITCSF1R
SCHEMBL4740129 0.88 KDR (0.75) KDRFLT3PDGFRBKITCSF1R
SCHEMBL4735281 0.86 KDR (0.65) KDRFLT3PDGFRBKITCSF1R
SCHEMBL4739162 0.86 KDR (0.66) KDRFLT3PDGFRBKITCSF1R
SCHEMBL421843 0.86 KDR (0.79) KDRFLT3PDGFRBKITCSF1R
SCHEMBL4739508 0.84 KDR (0.63) KDRFLT3PDGFRBKITCSF1R
SCHEMBL1383479 0.83 KDR (0.70) KDRFLT3PDGFRBKITCSF1R
SCHEMBL1379590 0.83 KDR (0.67) KDRFLT3PDGFRBKITCSF1R
SCHEMBL4787011 0.82 KDR (0.66) KDRFLT3PDGFRBKITCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4810427-B2 2011-11-09 JP claimed
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
EP-1638941-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-03-29 EP claimed
WO-2004113304-A1 INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-12-29 WO claimed
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO disclosed